NCT03069131 - Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

June 3, 2022

Study Completion Date

March 20, 2023

Conditions

CirrhosisAscitesPeritonitis

Interventions

DRUG

Rifaximin

twice daily administration of 1 tablet containing 550 mg of active rifaximin

OTHER

Placebo

twice daily administration of 1 rifaximin placebo tablet

Trial Locations (18)

CHU Caen, Caen

CHU Montpellier, Montpellier

CHU Tours, Tours

CHU Grenoble, La Tronche

Hopital de la croix-rousse, Lyon

CHU Rouen, Rouen

CHU Amiens, Amiens

CHU d'Angers, Angers

CHU de Besançon, Besançon

Hôpital Jean Verdier, Bondy

Hôpital Beaujon, Clichy

CHIC de Créteil, Créteil

CHRU de Lille, Lille

CHU de Nice, Nice

Hôpital Pitié Salpêtrière, Paris

CHU de Reims, Reims

CHU de Rennes, Rennes

CHU de Toulouse, Toulouse